Sangamo Therapeutics Announces Presentations At Upcoming Scientific, Medical And Investor Conferences
Upcoming Medical & Scientific Conferences
World Advanced Therapies and Regenerative Medicine Congress
"Gene Editing for Therapeutic Applications"
Friday, May 17th at 3:40 a.m. Eastern Time
London, United Kingdom
- Treg Directed Therapies Summit
"Engineering CAR Regulatory T Cells (CAR-Tregs) for Autoimmunity, Inflammation & Transplantation"
Wednesday, May 22nd at 9:30 a.m. Eastern Time
- Update on Fabry Disease Meeting
"Liver targeted AAV gene therapy vectors results in high levels of enzyme activity and effective substrate reduction in a mouse model of Fabry disease"
Sunday, May 26th at 10 a.m. Eastern Time
Prague, Czech Republic International Society on Thrombosis and Haemostasis(ISTH) Congress
"Initial results of the Alta study, a phase 1/2, open label, adaptive, dose-ranging study to assess the safety and tolerability of SB-525 gene therapy in adult subjects with severe hemophilia A"
Saturday, July 6th at 1:00 p.m.Australian Eastern Standard Time ( July 5th at 11 p.m. Eastern Time)
- Jefferies 2019 Healthcare Conference
Thursday, June 6th, at 1:30 p.m. Eastern Time
New York, NY
Members of the Sangamo management team will present a corporate overview at the Jefferies 2019 Healthcare Conference. The presentation will be webcast live and may be accessed via a link on the
About Sangamo Therapeutics
View original content to download multimedia:http://www.prnewswire.com/news-releases/sangamo-therapeutics-announces-presentations-at-upcoming-scientific-medical-and-investor-conferences-300851021.html
Investor Relations - United States: McDavid Stilwell, 510-970-6000, x219, email@example.com; Media Inquiries - United States: Aron Feingold, 510-970-6000, x421, firstname.lastname@example.org; Investor Relations and Media Inquiries - European Union: Caroline Courme, 33 4 97 21 27 27, email@example.com